乌比美克联合化疗治疗急、慢性白血病的临床研究

Clinical study of chemotherapy with Ubenimex Bestation in acute and chronic leubemin therapy

目的 探讨乌比美克的免疫调节作用。方法 乌比美克临床随机对照试验。结果 在 AML患者中 ,实验组的 CR期、生存期明显长于对照组 (平均 35 6 .6 5天和 44 4.6 3天 VS2 95 .5 9和 378.95天 ) ,实验组的中、重度感染率低于对照组。在 CML患者中 ,实验组的 CR率、CR期和慢性期均高于或长于对照组 (98.18%、35 2 .95天和 5 14天 VS6 0 %、2 46 .34天和 42 1.5 5天 ,P<0 .0 5 ) ,实验组的感染率、感染频度、轻度感染率和抗生素使用时间均低于对照组。两组细胞遗传学改变无显著性差异。 AML和 CML患者中 ,免疫综合疗效实验组均高于对照组。结论 乌比美克对 AML和

Objective To study adjunctive effect of ubenimex bestation (BS) of leukemia therapy.Methods Randomized control clinical trial.In addition of chemotherapy,BS were or not given separately to trial and control groups.Clinical responses were analyzed.Results In AML group,both the length of CR phase and the length of survival in trial group were much more longer than that of control group (means 356.65 day and 444.63 day vs.295.59 day and 378.95 day. P <0.05).Moderate and severe infection rate in trial group were lower than that of control group.IN CML group,CR rate,length of CR phase and length of chronic phase in trial proup were higher or longer than that of control group(98.18%,352.95 day and 514 day VS.60%,246.34 day and 421.55 day P <0.05)。In addition,total infection rate,infection frequency,mild infection rate and duration use of antibiotics were all lower in trial group than that of control group.There were no different cytogenetic changes both in trial and control groups.Both in AML and in CML groups,total immunologic effects were much more higher in trial group than that of control group.Conclusion BS had some adjunctive effect in AML and CML therapy.